First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China

Objective: The study aimed to assess the cost-effectiveness of sintilimab combined with cisplatin plus paclitaxel versus chemotherapy alone as first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma from the Chinese healthcare system. Materials and methods: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jian, Du, Yi, Shao, Rong, Jiang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767976/
https://www.ncbi.nlm.nih.gov/pubmed/36569294
http://dx.doi.org/10.3389/fphar.2022.967182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767976/
https://www.ncbi.nlm.nih.gov/pubmed/36569294
http://dx.doi.org/10.3389/fphar.2022.967182

Ejemplares similares